| 前收市價 | 1.6300 |
| 開市 | 1.5600 |
| 買盤 | 0.8800 |
| 賣出價 | 1.7600 |
| 拍板 | 135.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 1.5000 - 1.5600 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2.84k |
ZacksPharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
ZacksAbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Insider MonkeyIs AbbVie Inc. (NYSE:ABBV) the Most Undervalued Dividend Aristocrat Stock According to Analysts?
We recently compiled the list of 25 Best Dividend Aristocrats Stocks According to Analysts. Since AbbVie Inc. (NYSE:ABBV) is part of our list, we have analyzed the stock in detail. The age-old debate of investing in dividend growth or high-yield stocks continues to reappear within the dividend investing realm. Between these two, dividend growth is currently […]
